Skip to main content

Early versus Late Radiofrequency Catheter Ablation in Atrial Fibrillation: Timing Matters

Research Authors
Ahmad AA Farghaly, Hussam Ali, Pierpaolo Lupo, Sara Foresti, Guido De Ambroggi, Salah Atta, Ahmed Abdel-Galeel, Aly Tohamy, Riccardo Cappato
Research Date
Research Department
Research Journal
Journal of Clinical Medicine
Research Publisher
MDPI
Research Vol
Volume 13, Issue 16
Research Website
https://scholar.google.com.eg/scholar?oi=bibs&cluster=6382584112263734988&btnI=1&hl=en
Research Year
2024
Research_Pages
4643
Research Abstract

Despite the progressive course of atrial fibrillation (AF), the optimal timing of radiofrequency catheter ablation (RFCA) during disease course is still unknown. We aimed to investigate the impact of early RFCA within a year after AF diagnosis on procedural outcomes.

Methods

A single-center retrospective study was conducted on symptomatic AF patients (n = 130) referred for RFCA with a 16-month median follow-up. Patients were stratified based on the diagnosis-to-ablation time (DAT) into early (≤1 year) and late (>1 year) RFCA groups. Atrial arrhythmia recurrence after single RFCA was the primary outcome. Secondary outcomes included cardiovascular hospitalizations, AF progression, and antiarrhythmic drug (AAD) use.

Results

Within a year of AF diagnosis, 33 patients (25.4%) underwent RFCA. In the early-RFCA group, 84.4% of patients did not have recurrent atrial arrhythmia, in contrast to 60.8% in the late-RFCA group (p = 0.039). Late RFCA (HR = 2.74, 95% CI = 1.062–7.052, p = 0.037) and AF recurrence during the blanking period (HR = 4.57, 95% CI = 2.38–8.57, p < 0.0001) were independent predictors of atrial arrhythmia recurrence on multivariate analysis. Compared to the late-RFCA group, the early-RFCA group had significantly lower rates of cardiovascular hospitalizations (18% vs. 42%, p = 0.023), AF progression (0.0% vs. 11.3%, p = 0.044), and AAD use (45.4% vs. 81.4%, p < 0.001).

Conclusions

Early RFCA within a year of AF diagnosis is associated with less atrial arrhythmia recurrence, fewer cardiovascular hospitalizations, less AF progression, and less AAD use. DAT of more than one year and AF recurrence …